208 related articles for article (PubMed ID: 23674875)
1. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients.
Ishida K; Inoue T; Fujiwara K; Sakanaka T; Narabayashi K; Nouda S; Okada T; Kakimoto K; Kuramoto T; Kawakami K; Abe Y; Takeuchi T; Murano M; Tokioka S; Umegaki E; Higuchi K
World J Gastroenterol; 2013 May; 19(17):2676-82. PubMed ID: 23674875
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
3. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T;
J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn's disease.
Zhou S; Huang Z; Hou W; Lin Y; Yu J
Inflamm Res; 2024 Feb; 73(2):199-209. PubMed ID: 38168701
[TBL] [Abstract][Full Text] [Related]
7. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for maintenance of remission in Crohn's disease.
Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.
Watanabe M; Hibi T; Lomax KG; Paulson SK; Chao J; Alam MS; Camez A;
J Crohns Colitis; 2012 Mar; 6(2):160-73. PubMed ID: 22325170
[TBL] [Abstract][Full Text] [Related]
11. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
[TBL] [Abstract][Full Text] [Related]
12. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial.
Taxonera C; López-Sanromán A; Vera-Mendoza I; Domènech E; Ruiz VV; Marín-Jiménez I; Guardiola J; Castro L; Esteve M; Iglesias E; Ceballos D; Martínez-Montiel P; Gisbert JP; Mínguez M; Echarri A; Calvet X; Barrio J; Hinojosa J; Martín-Arranz MD; Márquez-Mosquera L; Bermejo F; Rimola J; Alba C; Pons V; Nos P;
Dig Liver Dis; 2019 Apr; 51(4):529-535. PubMed ID: 30712954
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
Kopylov U; Al-Taweel T; Yaghoobi M; Nauche B; Bitton A; Lakatos PL; Ben-Horin S; Afif W; Seidman EG
J Crohns Colitis; 2014 Dec; 8(12):1632-41. PubMed ID: 25067824
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
Savarino E; Bodini G; Dulbecco P; Assandri L; Bruzzone L; Mazza F; Frigo AC; Fazio V; Marabotto E; Savarino V
Am J Gastroenterol; 2013 Nov; 108(11):1731-42. PubMed ID: 24019080
[TBL] [Abstract][Full Text] [Related]
16. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.
López-Sanromán A; Vera-Mendoza I; Domènech E; Taxonera C; Vega Ruiz V; Marín-Jiménez I; Guardiola J; Castro L; Esteve M; Iglesias E; Ceballos D; Martínez-Montiel P; Gisbert JP; Mínguez M; Echarri A; Calvet X; Barrio J; Hinojosa J; Martín-Arranz MD; Márquez-Mosquera L; Bermejo F; Rimola J; Pons V; Nos P;
J Crohns Colitis; 2017 Oct; 11(11):1293-1301. PubMed ID: 28402454
[TBL] [Abstract][Full Text] [Related]
19. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
Chande N; Patton PH; Tsoulis DJ; Thomas BS; MacDonald JK
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD000067. PubMed ID: 26517527
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.
Takeshima F; Yoshikawa D; Higashi S; Morisaki T; Oda H; Ikeda M; Machida H; Matsushima K; Minami H; Akazawa Y; Yamaguchi N; Ohnita K; Isomoto H; Ueno M; Nakao K
BMC Gastroenterol; 2016 Jul; 16(1):82. PubMed ID: 27472988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]